Ferumoxytol: In iron deficiency anaemia in adults with chronic kidney disease

Drugs

Volumn 72, Issue 15, 2012, Pages 2013-2022

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Anaemia; Ferumoxytol; Iron deficiency anaemia

Indexed keywords

FERROUS FUMARATE; FERUMOXYTOL; PLACEBO;

ABDOMINAL PAIN; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; CHRONIC KIDNEY DISEASE; COUGHING; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; IRON DEFICIENCY ANEMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX PAIN; VOMITING;

ANEMIA, IRON-DEFICIENCY; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION ROUTES; FERUMOXYTOL; HUMANS; IRON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867311318     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209880-000000000-00000     Document Type: Article

References (29)

1. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006 May; 47 (5 Suppl. 3): S11-145
2. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010 Feb; 26 (2): 473-82
3. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 May; 19 Suppl. 2: ii1-47
4. National Institute for Health and Clinical Excellence (NICE). Anaemia management in people with chronic kidney disease [online]. Available from URL: http://www.guideline.gov/content.aspx?id=34281&search=anaemia#Section420 [Accessed 2012 Aug 22]
5. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007 Sep; 50 (3): 471-530
6. Amgen Inc. Epogen-(epoetin alfa): US prescribing information [online]. Available from URL: http://pi.amgen.com/united-states/epogen/epogen-pi-hcp- english.pdf [Accessed 2012 Aug 22]
7. Amgen Inc. Aranesp-(darbepoetin alfa): US prescribing information [online]. Available from URL: http://pi.amgen. com/united-states/aranesp/ckd/ aranesp-pi-hcp-english.pdf [Accessed 2012 Aug 22]
8. Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006 Mar-Apr; 19 (2): 161-7 (Pubitemid 44420105)
9. Coppol E, Shelly J, Cheng S. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population. Ann Pharmacother 2011 Feb; 45: 241-7
10. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011 Jan 4; 3 (1): 12-33
11. Sanofi-Aventis. Ferrlecit-(sodium ferric gluconate complex in sucrose, injection): US prescribing information [online]. Available from URL: http://products.sanofi.us/ferrlecit/ferrlecit.html [Accessed 2012 Aug 22]
12. Pharmacosmos UK. CosmoFer (low molecular weight iron dextran) 50 mg/mL solution for infusion and injection: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc/medicine/14139 [Accessed 2012 Aug 22]
13. Vifor Pharma UK. Venofer (iron sucrose): summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/ medicine/24168/SPC/Venofer +(iron+sucrose)/[Accessed 2012 Aug 22]
14. Vifor Pharma UK. Ferinject (ferric carboxymaltose): summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/ medicine/24167/SPC/Ferinject+(ferric+carboxymaltose)/[Accessed 2012 Aug 22]
15. Scottish Medicines Consortium. Iron isomaltoside 1000, 100 mg/mL solution for injection/infusion (Monofer ) [online]. Available fromURL: http://www.scottishmedicines. org.uk/files/advice/iron-isomaltoside-Monofer FINAL-APRIL-2011-amended-030511-for website.pdf [Accessed 2012 Aug 22]
16. Watson Pharma Inc. INFeD-(iron dextran injection USP): US prescribing information [online]. Available from URL: http://pi.watson.com/data stream.asp?product-group=1251 &p=pi&language=E [Accessed 2012 Aug 22]
17. US FDA. Dexferrum(iron dextran injection, USP): US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda docs/label/2009/040024s022lbl.pdf [Accessed 2012 Aug 22]
18. Takeda Pharmaceutical Company Limited, AMAG Pharmaceuticals Inc. Rienso (ferumoxytol) receives European marketing authorisation for the treatment of iron deficiency anaemia in adult chronic kidney disease patients [media release]. 2012 Jun 25 [online]. Available from URL: http://www.takeda.com/pdf/ usr/default/press/E-Press-Release-46752-1.pdf [Accessed 2012 Aug 22]
19. AMAG Pharmaceuticals Inc. Feraheme (ferumoxytol injection): US prescribing information [online]. Available from URL: http://www.feraheme.com/ wp-content/themes/ferahe me/documents/MARKETPI.pdf [Accessed 2012 Aug 22]
20. Rienso (ferumoxytol): summary of product characteristics. London: Takeda Global Research and Development Centre (Europe) Ltd, 2012 Jun
21. Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005 Oct; 68 (4): 1801-7 (Pubitemid 43169925)
22. Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009 Feb; 4 (2): 386-93
23. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009 June; 39 (6): 489-96
24. Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005 Jul-Aug; 25 (4): 400-10 (Pubitemid 41160999)
25. Pai AB, Nielsen JC, Kausz A, et al. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther 2010 Aug; 88 (2): 237-42
26. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008 Aug; 19 (8): 1599-605
27. Sharma A, Bhat P, Schiller B, et al. Efficacy of Feraheme (ferumoxytol) administration on target hemoglobin levels and other iron parameters across 3 dialysis chains [abstract no. FR-PO1603 plus poster]. American Society of Nephrology Kidney Week 2011; 2011 Nov 8-13; Philadelphia (PA)
28. Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008 Nov; 52 (5): 907-15
29. Schiller B, Bhat P, Sharma A, et al. Safety of Feraheme (ferumoxytol) in hemodialysis patients at 3 dialysis chains over a 1-year period [abstract no. FR-PO1573 plus poster]. American Society of Nephrology Kidney Week 2011; 2011 Nov 8-13; Philadelphia (PA)